Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2004405 | 0.89 | IDO1 (0.37) | MAP2K1BRAFKMT2ATDP1 | |
| SCHEMBL1992988 | 0.82 | TDP1 (0.36) | MAP2K1MAPTBRAFTDP1 | |
| SCHEMBL12540652 | 0.77 | MAP2K1 (0.47) | MAP2K1 | |
| SCHEMBL1341935 | 0.77 | BRD4 (0.34) | MAP2K1MAPTTP53NMT1BRAF | |
| SCHEMBL1980229 | 0.74 | MAP2K1 (0.42) | MAP2K1 | |
| SCHEMBL1343639 | 0.72 | TDP1 (0.41) | MAP2K1MAPTTP53BRAFKMT2A | |
| SCHEMBL1992129 | 0.71 | IDO1 (0.38) | MAP2K1BRAF | |
| SCHEMBL1516484 | 0.70 | MAP2K1 (0.58) | MAP2K1BRAFALOX15TSHR | |
| SCHEMBL4230018 | 0.69 | KMT2A (0.46) | MAP2K1NMT1BRAFALOX15TSHR | |
| SCHEMBL1984529 | 0.69 | ALOX15 (0.32) | NMT1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509964-B1 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2014-04-30 | — | — | EP | claimed |
| US-8614239-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | claimed |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | claimed |
| EP-2509964-B1 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-8614239-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011070030-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | BRAF, NRAS, MAP3K1 | MAP2K1 103/4885MAPT 4586/4885TP53 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.